Clara Delaunay
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
Hippo pathway signaling and YAP/TAZ, Protein Degradation and Inhibitors, Ubiquitin and proteasome pathways, Plant Surface Properties and Treatments, Cell death mechanisms and regulation
Most-Cited Works
- → Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening(2017)693 cited
- → Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers(2024)114 cited
- → The Tyrosine Phosphatase PTPN14 Is a Negative Regulator of YAP Activity(2013)94 cited
- → Effect of the acylation of TEAD4 on its interaction with co‐activators YAP and TAZ(2017)69 cited
- → Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD(2017)56 cited
- → Identification of FAM181A and FAM181B as new interactors with the TEAD transcription factors(2019)35 cited
- → A Uniform Benchmark for Testing SsrA-Derived Degrons in the Escherichia coli ClpXP Degradation Pathway(2021)12 cited
- → Author Correction: Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers(2024)7 cited
- → Author response: Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD(2017)
- → A uniform benchmark for testing ssrA-derived degrons in the Escherichia coli ClpXP pathway(2021)